Research progress of pharmacogenomics of new oral anticoagulant

Author: Di MEI ¹ ; Chunyan LIU ¹ ; Chengcan LU ¹ ; Di MEI ² ; Jizhong SHEN ² ; Chunyan LIU ² ; Chengcan LU ² ; Wei XU ³ ; Yuzhu PENG ⁴
Author Information

1. Nanjing Drum Tower Hospital of China Pharmaceutical University
2. Department of Pharmacy, Drum Tower Hospital, Nanjing University School of Medicine
3. Department of Caidiovascular Medicine, Drum Tower Hopital, Nanjing University School of Medicine
4. Nanjing Municipal Health Commission
Publication Type:Journal Article
Keywords: Gene polymorphism; New oral anticoagulants; Pharmacokinetic pharmacogenomics
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2021;26(10):1200-1207
CountryChina
Language:Chinese
Abstract: The new oral anticoagulants (NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban are widely used in clinical anticoagulation because of their fixed doses and superior safety. Studies have pointed out that there are large inter-individual differences in the pharmacokinetic parameters and response of NOAC, which may be related to the genetic polymorphisms of transporters and metabolic enzymes involved in in-vivo processes. This article reviews the influence of gene polymorphism on the pharmacokinetics and adverse reactions of NOAC, and provides directions for future research.